{"id":70274,"date":"2026-07-20T14:10:17","date_gmt":"2026-07-20T06:10:17","guid":{"rendered":"https:\/\/flcube.com\/?p=70274"},"modified":"2026-07-20T14:10:18","modified_gmt":"2026-07-20T06:10:18","slug":"mabwell-secures-nmpa-ind-approval-for-9mw5211-injection-in-vitiligo-expanding-multi-indication-autoimmune-pipeline-with-highly-selective-depleting-antibody","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70274","title":{"rendered":"Mabwell Secures NMPA IND Approval for 9MW5211 Injection in Vitiligo, Expanding Multi-Indication Autoimmune Pipeline with Highly Selective Depleting Antibody"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Mabwell (Shanghai) Bioscience Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688062:SHA\">SHA: 688062<\/a>) announced that its <strong>Investigational New Drug (IND) application for 9MW5211 injection<\/strong> for the treatment of <strong>vitiligo<\/strong> has been approved by <strong>China&#8217;s National Medical Products Administration (NMPA)<\/strong>. This approval expands Mabwell&#8217;s growing autoimmune disease pipeline, following previous IND clearances for <strong>inflammatory bowel disease (IBD)<\/strong> by both NMPA and FDA, and for <strong>multiple sclerosis (MS)<\/strong> and <strong>type 1 diabetes mellitus (T1DM)<\/strong> by NMPA.<\/p>\n\n\n\n<h2 id=\"h-clinical-development-pipeline-status\" class=\"wp-block-heading\">Clinical Development Pipeline Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Regulatory Authority<\/th><th>Approval Status<\/th><th>Development Stage<\/th><\/tr><\/thead><tbody><tr><td><strong>Vitiligo<\/strong><\/td><td>NMPA (China)<\/td><td><strong>Approved<\/strong> (20 Jul 2026)<\/td><td>Pre-clinical \u2192 Phase I<\/td><\/tr><tr><td><strong>Inflammatory Bowel Disease (IBD)<\/strong><\/td><td>NMPA (China)<\/td><td>Approved<\/td><td>Clinical development<\/td><\/tr><tr><td><strong>Inflammatory Bowel Disease (IBD)<\/strong><\/td><td>FDA (USA)<\/td><td>Cleared<\/td><td>Clinical development<\/td><\/tr><tr><td><strong>Multiple Sclerosis (MS)<\/strong><\/td><td>NMPA (China)<\/td><td>Approved<\/td><td>Clinical development<\/td><\/tr><tr><td><strong>Type 1 Diabetes Mellitus (T1DM)<\/strong><\/td><td>NMPA (China)<\/td><td>Approved<\/td><td>Clinical development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> 9MW5211 \u2013 highly specific depleting innovative antibody<\/li>\n\n\n\n<li><strong>Target:<\/strong> Surface protein specifically expressed on pathogenic immune cells serving as biomarker for abnormal activation<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Selective recognition and depletion of pathogenic immune cells driving autoimmune disease progression<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> Blocks immune cascade response by eliminating core drivers of autoimmune pathology \u2013 abnormal activation and tissue infiltration of immune cells<\/li>\n\n\n\n<li><strong>Key Differentiators:<\/strong><\/li>\n\n\n\n<li><strong>Exceptional target selectivity<\/strong> minimizing non-specific binding<\/li>\n\n\n\n<li><strong>Profound depletion<\/strong> of pathogenic cells with high target protein expression<\/li>\n\n\n\n<li><strong>Reduced safety risks<\/strong> through precise targeting of disease-causing cells only<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-autoimmune-disease-market-opportunity\" class=\"wp-block-heading\">Autoimmune Disease Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Global Prevalence<\/th><th>Current Treatment Limitations<\/th><th>9MW5211 Value Proposition<\/th><\/tr><\/thead><tbody><tr><td><strong>Vitiligo<\/strong><\/td><td>50-100 million patients globally<\/td><td>Limited effective treatments; repigmentation challenges<\/td><td>First targeted therapy addressing root immune cause<\/td><\/tr><tr><td><strong>IBD (Crohn&#8217;s\/Ulcerative Colitis)<\/strong><\/td><td>10+ million patients globally<\/td><td>Inadequate response rates; safety concerns with broad immunosuppression<\/td><td>Precise pathogenic cell depletion vs. general immunosuppression<\/td><\/tr><tr><td><strong>Multiple Sclerosis<\/strong><\/td><td>2.8 million patients globally<\/td><td>Progressive disability despite current therapies<\/td><td>Potential to halt disease progression at cellular source<\/td><\/tr><tr><td><strong>Type 1 Diabetes<\/strong><\/td><td>8+ million patients globally<\/td><td>Insulin replacement only; no disease-modifying therapies<\/td><td>First potential disease-modifying approach targeting autoimmune destruction<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-development-advantages\" class=\"wp-block-heading\">Strategic Development Advantages<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Technology:<\/strong> Single molecule applicable across multiple autoimmune indications with shared pathological mechanisms<\/li>\n\n\n\n<li><strong>Regulatory Momentum:<\/strong> Simultaneous development in China and U.S. markets accelerates global commercialization timeline<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Highly selective mechanism differentiates from broad immunosuppressants and less specific biologics<\/li>\n\n\n\n<li><strong>Manufacturing Efficiency:<\/strong> Common production process across indications reduces development costs and complexity<\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Independently developed by Mabwell with strong global patent protection expected<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-investment-amp-commercial-implications\" class=\"wp-block-heading\">Investment &amp; Commercial Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Valuation:<\/strong> Multi-indication approach significantly increases asset value compared to single-indication programs<\/li>\n\n\n\n<li><strong>Market Entry Strategy:<\/strong> Potential for premium pricing in vitiligo market where effective treatments are severely limited<\/li>\n\n\n\n<li><strong>Partnership Opportunities:<\/strong> Strong clinical data could attract global pharmaceutical partnerships for non-China territories<\/li>\n\n\n\n<li><strong>Development Timeline:<\/strong> Vitiligo indication may offer faster regulatory pathway due to high unmet medical need<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Combined autoimmune market opportunity exceeds $50 billion annually across all four indications<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development timelines, and commercial prospects for 9MW5211. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><br><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688062_20260716_HPEA.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688062_20260716_HPEA.\"><\/object><a id=\"wp-block-file--media-93c0c844-6a30-4f19-bed6-f309a8492618\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688062_20260716_HPEA.pdf\">688062_20260716_HPEA<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688062_20260716_HPEA.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-93c0c844-6a30-4f19-bed6-f309a8492618\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that its Investigational New Drug (IND) application&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,118,1129],"class_list":["post-70274","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-mabwell-bioscience","tag-sha-688062"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Mabwell Secures NMPA IND Approval for 9MW5211 Injection in Vitiligo, Expanding Multi-Indication Autoimmune Pipeline with Highly Selective Depleting Antibody - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that its Investigational New Drug (IND) application for 9MW5211 injection for the treatment of vitiligo has been approved by China&#039;s National Medical Products Administration (NMPA). This approval expands Mabwell&#039;s growing autoimmune disease pipeline, following previous IND clearances for inflammatory bowel disease (IBD) by both NMPA and FDA, and for multiple sclerosis (MS) and type 1 diabetes mellitus (T1DM) by NMPA.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70274\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mabwell Secures NMPA IND Approval for 9MW5211 Injection in Vitiligo, Expanding Multi-Indication Autoimmune Pipeline with Highly Selective Depleting Antibody\" \/>\n<meta property=\"og:description\" content=\"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that its Investigational New Drug (IND) application for 9MW5211 injection for the treatment of vitiligo has been approved by China&#039;s National Medical Products Administration (NMPA). This approval expands Mabwell&#039;s growing autoimmune disease pipeline, following previous IND clearances for inflammatory bowel disease (IBD) by both NMPA and FDA, and for multiple sclerosis (MS) and type 1 diabetes mellitus (T1DM) by NMPA.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70274\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-20T06:10:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-20T06:10:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70274#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70274\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Mabwell Secures NMPA IND Approval for 9MW5211 Injection in Vitiligo, Expanding Multi-Indication Autoimmune Pipeline with Highly Selective Depleting Antibody\",\"datePublished\":\"2026-07-20T06:10:17+00:00\",\"dateModified\":\"2026-07-20T06:10:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70274\"},\"wordCount\":505,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Mabwell Bioscience\",\"SHA: 688062\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70274#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70274\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70274\",\"name\":\"Mabwell Secures NMPA IND Approval for 9MW5211 Injection in Vitiligo, Expanding Multi-Indication Autoimmune Pipeline with Highly Selective Depleting Antibody - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-20T06:10:17+00:00\",\"dateModified\":\"2026-07-20T06:10:18+00:00\",\"description\":\"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that its Investigational New Drug (IND) application for 9MW5211 injection for the treatment of vitiligo has been approved by China's National Medical Products Administration (NMPA). This approval expands Mabwell's growing autoimmune disease pipeline, following previous IND clearances for inflammatory bowel disease (IBD) by both NMPA and FDA, and for multiple sclerosis (MS) and type 1 diabetes mellitus (T1DM) by NMPA.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70274#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70274\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70274#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mabwell Secures NMPA IND Approval for 9MW5211 Injection in Vitiligo, Expanding Multi-Indication Autoimmune Pipeline with Highly Selective Depleting Antibody\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mabwell Secures NMPA IND Approval for 9MW5211 Injection in Vitiligo, Expanding Multi-Indication Autoimmune Pipeline with Highly Selective Depleting Antibody - Insight, China&#039;s Pharmaceutical Industry","description":"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that its Investigational New Drug (IND) application for 9MW5211 injection for the treatment of vitiligo has been approved by China's National Medical Products Administration (NMPA). This approval expands Mabwell's growing autoimmune disease pipeline, following previous IND clearances for inflammatory bowel disease (IBD) by both NMPA and FDA, and for multiple sclerosis (MS) and type 1 diabetes mellitus (T1DM) by NMPA.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70274","og_locale":"en_US","og_type":"article","og_title":"Mabwell Secures NMPA IND Approval for 9MW5211 Injection in Vitiligo, Expanding Multi-Indication Autoimmune Pipeline with Highly Selective Depleting Antibody","og_description":"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that its Investigational New Drug (IND) application for 9MW5211 injection for the treatment of vitiligo has been approved by China's National Medical Products Administration (NMPA). This approval expands Mabwell's growing autoimmune disease pipeline, following previous IND clearances for inflammatory bowel disease (IBD) by both NMPA and FDA, and for multiple sclerosis (MS) and type 1 diabetes mellitus (T1DM) by NMPA.","og_url":"https:\/\/flcube.com\/?p=70274","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-20T06:10:17+00:00","article_modified_time":"2026-07-20T06:10:18+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70274#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70274"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Mabwell Secures NMPA IND Approval for 9MW5211 Injection in Vitiligo, Expanding Multi-Indication Autoimmune Pipeline with Highly Selective Depleting Antibody","datePublished":"2026-07-20T06:10:17+00:00","dateModified":"2026-07-20T06:10:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70274"},"wordCount":505,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Mabwell Bioscience","SHA: 688062"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70274#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70274","url":"https:\/\/flcube.com\/?p=70274","name":"Mabwell Secures NMPA IND Approval for 9MW5211 Injection in Vitiligo, Expanding Multi-Indication Autoimmune Pipeline with Highly Selective Depleting Antibody - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-20T06:10:17+00:00","dateModified":"2026-07-20T06:10:18+00:00","description":"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that its Investigational New Drug (IND) application for 9MW5211 injection for the treatment of vitiligo has been approved by China's National Medical Products Administration (NMPA). This approval expands Mabwell's growing autoimmune disease pipeline, following previous IND clearances for inflammatory bowel disease (IBD) by both NMPA and FDA, and for multiple sclerosis (MS) and type 1 diabetes mellitus (T1DM) by NMPA.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70274#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70274"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70274#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mabwell Secures NMPA IND Approval for 9MW5211 Injection in Vitiligo, Expanding Multi-Indication Autoimmune Pipeline with Highly Selective Depleting Antibody"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70274","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70274"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70274\/revisions"}],"predecessor-version":[{"id":70276,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70274\/revisions\/70276"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70274"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70274"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70274"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}